A 7-year-old boy is brought to the child psychiatry clinic by his mother with complaints of inattention and hyperactivity for the past 18 months. The teacher reports that he is unable to sit still in class, frequently interrupts others, and loses his school materials. At home, he has difficulty completing homework and often forgets instructions. On examination, he is restless, fidgets constantly, and has difficulty maintaining eye contact during conversation. His developmental milestones were normal, and there is no history of seizures, head injury, or significant medical illness. Psychometric testing shows average intelligence. The mother mentions that his father had similar difficulties in school. What is the most appropriate first-line pharmacological intervention for this child?

Explanation

## Diagnosis and Management of ADHD ### Clinical Presentation This child presents with the classic triad of ADHD: 1. **Inattention** — loses materials, forgetfulness, difficulty with tasks 2. **Hyperactivity** — restlessness, fidgeting, inability to sit still 3. **Impulsivity** — interrupting, difficulty waiting turns Symptoms are present across multiple settings (school and home) for >6 months, supporting the diagnosis [cite:DSM-5]. ### Pharmacological Management Algorithm ```mermaid flowchart TD A[ADHD diagnosis confirmed]:::outcome --> B{First-line pharmacotherapy?}:::decision B -->|Stimulants| C[Methylphenidate or Amphetamine salts]:::action B -->|Non-stimulant| D[Atomoxetine or Guanfacine]:::action C --> E[Start low dose, titrate weekly]:::action E --> F[Monitor BP, HR, appetite]:::action F --> G[Assess efficacy at 4 weeks]:::outcome D --> H[Consider if stimulant intolerance/abuse risk]:::action ``` ### Why Methylphenidate is First-Line **Key Point:** Stimulant medications (methylphenidate and amphetamine salts) are the gold standard first-line pharmacological treatment for ADHD in children [cite:Harrison 21e Ch 387]. **High-Yield:** Methylphenidate: - **Mechanism:** Blocks reuptake of dopamine and norepinephrine in prefrontal cortex - **Onset:** 30–60 minutes (immediate-release); 4–8 hours (extended-release) - **Efficacy:** 70–80% response rate in ADHD - **Dosing:** Start 5 mg once or twice daily; titrate by 5 mg weekly to max 60 mg/day - **Monitoring:** Blood pressure, heart rate, appetite, growth, sleep **Clinical Pearl:** Non-pharmacological interventions (behavioral therapy, parent training, school accommodations) should ALWAYS accompany pharmacotherapy — medication alone is insufficient [cite:Park 26e Ch 15]. ### Comparison of ADHD Pharmacotherapy | Agent | Class | Onset | Duration | First-Line? | Monitoring | |-------|-------|-------|----------|-------------|------------| | **Methylphenidate** | Stimulant | 30–60 min | 3–4 hrs (IR); 8–12 hrs (ER) | **Yes** | BP, HR, appetite, growth | | **Amphetamine salts** | Stimulant | 30–60 min | 4–6 hrs (IR); 10–13 hrs (ER) | **Yes** | BP, HR, appetite, growth | | **Atomoxetine** | Non-stimulant | 2–4 weeks | 24 hrs | No (second-line) | Liver function, BP | | **Guanfacine** | α~2~-agonist | 1–2 weeks | 12–16 hrs | No (second-line) | BP, HR, sedation | ### When to Use Non-Stimulants **Warning:** Reserve atomoxetine and guanfacine for: - Stimulant intolerance or adverse effects - Tics or Tourette syndrome (stimulants may worsen) - Substance abuse risk in adolescents - Comorbid anxiety or sleep disturbance ### Contraindications to Stimulants - Uncontrolled hypertension - Cardiac arrhythmias or structural heart disease - Active psychosis - Severe anxiety (may exacerbate) **Tip:** Always obtain baseline BP, HR, and weight before starting; repeat at each visit during titration.